Kaplan-Meier analysis of the cumulative incidence of MCR achievement.

(A) According to combined Sokal score and IFN-αR2c/G6PDH ratio, the 73 patients were separated into 4 groups: group I, low-risk Sokal score (LR) and IFN-αR2c/G6PDH ratio less than 78.83%; group II, low-risk Sokal score and IFN-αR2c/G6PDH ratio greater than 78.83%; group III, intermediate/high-risk Sokal score (IR-HR) and IFN-αR2c/G6PDH ratio less than 78.83%; and group IV, intermediate/high-risk Sokal score and IFN-αR2c/G6PDH ratio greater than 78.83%. The cumulative incidence of MCR achievement was significantly lower for patients with an intermediate/high-risk Sokal score and an IFN-αR2c/G6PDH ratio less than 78.83% (P  < .004) than for patients in the 3 other groups, among which there were no significant differences. For groups III, II, I, and IV, the probability of achieving MCR at 12 months was 15% ± 15%, 51% ± 24%, 55% ± 28%, and 54% ± 30%, respectively; at 24 months it was 20% ± 17%, 68% ± 25%, 76% ± 27%, and 85% ± 27%, respectively. (B) According to the combined IFN-αR2/G6PDH ratio at diagnosis and CHR at 3 months for the 74 patients with CML. Group A, patients who had an IFN-αR2/G6PDH ratio of 78.83% or greater and CHR at 3 months. Group B, patients who had an IFN-αR2/G6PDH ratio of 78.83% or greater or CHR at 3 months, but not both. Group C, patients who had neither an IFN-αR2/G6PDH ratio of 78.83% or greater nor CHR at 3 months. For all 3 groups, the cumulative incidence of MCR at 12 months was 72% ± 26%, 43% ± 19%, and 19% ± 17%, respectively. At 24 months, it was 91% ± 17%, 58% ± 20%, and 30% ± 20%, respectively.